000178415 001__ 178415
000178415 005__ 20240229133806.0
000178415 0247_ $$2doi$$a10.1038/s41598-021-02958-w
000178415 0247_ $$2pmid$$apmid:34876619
000178415 0247_ $$2pmc$$apmc:PMC8651788
000178415 0247_ $$2altmetric$$aaltmetric:118436933
000178415 037__ $$aDKFZ-2022-00042
000178415 041__ $$aEnglish
000178415 082__ $$a600
000178415 1001_ $$aObi, Nadia$$b0
000178415 245__ $$aAssociation of circulating leptin, adiponectin, and resistin concentrations with long-term breast cancer prognosis in a German patient cohort.
000178415 260__ $$a[London]$$bMacmillan Publishers Limited, part of Springer Nature$$c2021
000178415 3367_ $$2DRIVER$$aarticle
000178415 3367_ $$2DataCite$$aOutput Types/Journal article
000178415 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1641821277_5388
000178415 3367_ $$2BibTeX$$aARTICLE
000178415 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000178415 3367_ $$00$$2EndNote$$aJournal Article
000178415 500__ $$a#LA:C020#
000178415 520__ $$aAdipokines including leptin, adiponectin and resistin have been linked to risk of obesity-related cancers potentially through low-grade chronic inflammation pathways. We aimed to assess the role of post-diagnosis circulating adipokines on long-term prognosis in a prospective breast cancer cohort. Adipokines were measured in blood collected at baseline shortly after diagnosis (2002-2005) and at follow-up (2009) from 3112 breast cancer patients enrolled in the population-based MARIE study. Half of the patients had measurements at both time-points. All-cause mortality, breast cancer specific mortality and recurrences were ascertained up to June 2015 (11 years median follow-up). Associations with time-varying adipokine concentrations overall and stratified by estrogen and progesterone receptor (ERPR) were evaluated using adjusted proportional hazard regression. At baseline (n = 2700) and follow-up (n = 2027), median concentrations for leptin, adiponectin and resistin were 4.6 and 2.7 ng/ml, 24.4 and 30.0 mg/l, 15.4 and 26.2 ng/ml, respectively. After adjustment, there was no evidence for associations between adipokines and any outcome overall. In ERPR negative tumors, highest vs. lowest quintile of adiponectin was significantly associated with increased breast cancer specific mortality (HR 2.51, 95%CI 1.07-5.92). Overall, post-diagnosis adipokines were not associated with long-term outcomes after breast cancer. In patients with ERPR negative tumors, higher concentrations of adiponectin may be associated with increased breast cancer specific mortality and warrant further investigation.
000178415 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000178415 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000178415 7001_ $$0P:(DE-He78)bce1fdec5ce564e2666156d96aeabec9$$aJung, Audrey Y$$b1$$udkfz
000178415 7001_ $$aMaurer, Tabea$$b2
000178415 7001_ $$aHuebner, Marianne$$b3
000178415 7001_ $$0P:(DE-He78)79ab945544e5bc017a2317b6146ed3aa$$aJohnson, Theron$$b4$$udkfz
000178415 7001_ $$0P:(DE-He78)6b04712f3afe72044d496a25505cb1ea$$aBehrens, Sabine$$b5$$udkfz
000178415 7001_ $$0P:(DE-He78)e16e2a17f7dd2e7f7e917c0382f19b2d$$aJaskulski, Stefanie$$b6
000178415 7001_ $$aBecher, Heiko$$b7
000178415 7001_ $$0P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aChang-Claude, Jenny$$b8$$eLast author$$udkfz
000178415 773__ $$0PERI:(DE-600)2615211-3$$a10.1038/s41598-021-02958-w$$gVol. 11, no. 1, p. 23526$$n1$$p23526$$tScientific reports$$v11$$x2045-2322$$y2021
000178415 909CO $$ooai:inrepo02.dkfz.de:178415$$pVDB
000178415 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bSCI REP-UK : 2019$$d2021-02-03
000178415 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-02-03
000178415 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-02-03
000178415 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2021-02-03
000178415 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-02-03
000178415 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-02-03
000178415 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2021-02-03
000178415 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-02-03
000178415 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2021-02-03
000178415 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2021-02-03
000178415 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-02-03
000178415 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-03
000178415 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2021-02-03
000178415 915__ $$0StatID:(DE-HGF)1150$$2StatID$$aDBCoverage$$bCurrent Contents - Physical, Chemical and Earth Sciences$$d2021-02-03
000178415 915__ $$0StatID:(DE-HGF)1040$$2StatID$$aDBCoverage$$bZoological Record$$d2021-02-03
000178415 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-02-03
000178415 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-03
000178415 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-02-03
000178415 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2021-02-03
000178415 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-02-03
000178415 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-02-03
000178415 9141_ $$y2021
000178415 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bce1fdec5ce564e2666156d96aeabec9$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000178415 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)79ab945544e5bc017a2317b6146ed3aa$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000178415 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6b04712f3afe72044d496a25505cb1ea$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000178415 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e16e2a17f7dd2e7f7e917c0382f19b2d$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000178415 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000178415 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000178415 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000178415 980__ $$ajournal
000178415 980__ $$aVDB
000178415 980__ $$aI:(DE-He78)C020-20160331
000178415 980__ $$aUNRESTRICTED